RiboPro announced it has successfully closed a funding round of €1.2 million, led by Stichting Vlasroot, with a consortium of BOM, Rockstart, and several private investors contributing to this round.

The new funding will be used to advance RiboPro’s proprietary messenger RNA (mRNA) technology, strengthen the team, and scale the business. With its high-performance RNA products, RiboPro supports researchers and medicine developers worldwide in the adoption of the promising mRNA technology.

Read the full press release here.